Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.49 |
| ▸ | ERG | P11308 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14850683 | 1.00 | TACR3 (0.49) | TACR3KCNH2ERGCYP2C9CYP2C19 | |
| SCHEMBL17656103 | 0.78 | TACR3 (0.49) | TACR3KCNH2ERGCYP2C9CYP2C19 | |
| SCHEMBL17656121 | 0.78 | TACR3 (0.57) | TACR3KCNH2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL14850731 | 0.78 | TACR3 (0.49) | TACR3KCNH2ERGCYP2C9CYP2C19 | |
| SCHEMBL14850676 | 0.78 | TACR3 (0.57) | TACR3KCNH2CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL14850792 | 0.77 | TACR3 (0.54) | TACR3KCNH2ERGCYP2C9CYP2C19 | |
| SCHEMBL17804398 | 0.77 | TACR3 (0.54) | TACR3KCNH2ERGCYP2C9CYP2C19 | |
| SCHEMBL14850757 | 0.75 | TACR3 (0.52) | TACR3KCNH2ERG | |
| SCHEMBL16047691 | 0.75 | TACR3 (0.52) | TACR3KCNH2ERG | |
| SCHEMBL14850775 | 0.75 | TACR3 (0.52) | TACR3KCNH2ERG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763992-B9 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, AND METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS | EUROSCREEN SA (BE) | 2016-08-24 | — | — | EP | disclosed |
| EP-3029042-A1 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | Euroscreen S.A. (BE) | 2016-06-08 | — | — | EP | disclosed |
| EP-2763992-B1 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, AND METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS | EUROSCREEN SA (BE) | 2016-04-06 | — | — | EP | disclosed |
| WO-2013050424-A1 | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF | EUROSCREEN S.A. (BE) | 2013-04-11 | — | — | WO | disclosed |